INTRODUCTION AND OBJECTIVES: Heat-shock factor 1 (HSF1) is the master transcriptional regulator of the cellular response to various proteotoxic stressors. HSF1 has the pro-oncogenic potential and recent reports revealed that the transcriptional programs regulated by HSF1 are commonly activated in a range of human malignancies. Although high levels of HSF1 has been shown to predict poor survival in several cancers, predictive and prognostic role of HSF1 in bladder cancer is unexplored. The aim of this study was to evaluate associations of HSF1 expression with oncological outcomes in muscle-invasive bladder cancer (MIBC) patients treated with chemoradiotherapy (CRT)-based bladder sparing protocol.
METHODS: We performed immunohistochemical analysis of HSF1 expressions in bladder cancer tissues obtained from 52 MIBC patients who were treated with CRT-based bladder sparing protocol. According to the protocol, the patients underwent maximal transurethral resection and induction CRT (40 Gy with concurrent cisplatin), followed by consolidative partial cystectomy for bladder preservation or radical cystectomy. Associations of HSF1 expression status with response to CRT and cancerspecific survival (CSS) were evaluated by logistic and Cox regression analysis.
RESULTS: After induction CRT, 28 (54%) achieved clinical CR. Seven (13%) and 27 (52%) patients underwent partial and radical cystectomy, respectively, while the remaining 18 (35%) had no surgery (the overall 5-year CSS rate: 51%). High expression of HSF1 was observed in 29 (56%) of the 52 patients and was associated with poor response to CRT (clinical CR rate; 8/29 [28%] in HSF1 high vs 15/23 [65%] in HSF1 low, p<0.01). The patients with high expression of HSF1 had worse CSS compared to those with low HSF1 expression (5-year CSS rate; 34% for HSF1 high vs 75% for HSF1 low, p[0.01). Among the clinical variables, high HSF1 expression, cT3-4 tumor, and non-curative resection at initial transurethral resection were independently associated with an increased risk of cancer death.
CONCLUSIONS: High expression of HSF1 is associated with poor response to CRT and decreased survival in MIBC patients receiving CRT-based bladder sparing protocol. Our findings indicate that HSF1 is a potential biomarker and could be a therapeutic target to overcome chemo-and radioresistance in MIBC. 
INTRODUCTION AND OBJECTIVES:
Medical imaging is routinely used for the diagnosis and treatment of cancer. Via years of genomics testing hallmark mutations have been identified to characterize certain cancers. However, owing to the rapidly evolving mutational landscape, it is currently impossible to obtain a reliable assessment of tumor heterogeneity. Imaging is a clinically accepted technique in both clinical trials as well as routine practice and, easy to incorporate in longitudinal studies. Establishing reliable associations between imaging-based metrics (radiomics) and frequently mutated genes related to oncogenicity can be of great value in cancer management, particularly for muscle-invasive bladder cancer (MIBC).
METHODS: We integrated genomics data from The Cancer Genome Atlas (TCGA) with CT data from The Cancer Imaging Archive (TCIA) in 89 biopsy-proven MIBC cancer patients to find associations between hallmark MIBC mutations and radiomic metrics. Using an in-house developed Matlab code, a CT-based texture analysis panel comprising of texture metrics extracted using six different methods: histogram analysis, 2D-Gray-level cooccurrence matrix (GLCM), Gray-level difference matrix (GLDM) and Gray-level run-length matrix (GLRLM) and 2D-Fast Fourier Transform (FFT) analyses was applied to the segmented images. The extracted 488 texture features were associated with the genetic profiles of 16 mutations of MIBC namely ARID1A, ASXL2, ATM, CASP8, CDKN1A, CREBBP, ELF3, ERBB2, FGFR3, KDM6A, KMT2D, PIK3CA, RB1, RHOB, TP53 and EP300. 488 x 16 pairs of t-tests or Wilcoxon rank sum tests were used to create a panel of associations and studied using a heatmap of univariate p-values.
RESULTS: Amongst the 16 mutations, radiomic metrics showed strong associations with ARIDIA, FGFR3 and EP300 mutations, evident from the increased percent of radiomic metrics with a pvalue <0.05 among the 488 radiomics metrics i.e., 16.6%, 14.6% and 16.6% respectively. Of all the radiomics metrics, GLDM2D showed most associations particularly with ARIDIA, FGFR3 and EP300 mutations.
CONCLUSIONS: Our discovery analysis reveals promise in finding significant associations between non-invasive quantitative imaging metrics and genetic mutations, which would pave the way for further studies investigating this association. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e441
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